Not Interchangeable: Choosing Between Two GLP-1 Drugs After a Head-to-Head Trial
A 38-year-old woman with obesity and no diabetes asks whether semaglutide and tirzepatide are 'basically the same drug' — a question the SURMOUNT-5 head-to-head trial has since given a real, quantified answer to.
Renata S., a 38-year-old graphic designer, came to her appointment having already decided she wanted 'the GLP-1 shot,' a phrase she used interchangeably for two different drugs throughout the visit until her physician gently stopped her to ask which one she meant. She has a BMI of 34, no diabetes, and a family history of obesity on both sides that she describes with more humor than distress — her words were that she'd 'inherited the metabolism, not the strategy for dealing with it.' A coworker's visible weight loss on what turned out to be tirzepatide, and a cousin's more modest but still real results on semaglutide, had left her with the impression that the two were essentially the same drug under different names.
That impression isn't unreasonable on the surface — both are once-weekly injectable incretin-pathway drugs, both produce substantial weight loss compared to placebo, and both were, until recently, only compared indirectly across separate trials with different populations. That changed with SURMOUNT-5, a randomized head-to-head trial that put 751 adults with obesity but no diabetes on one drug or the other at maximum tolerated dose and measured the actual difference rather than inferring one. Renata's own profile — obesity without diabetes, no established cardiovascular disease, otherwise healthy — sits close enough to that trial's population that its result bears directly on her decision, not just on the field in general.
She'd also mentioned, almost in passing while describing her cousin's experience, that he'd struggled with nausea badly enough in his first month that he'd nearly quit — a detail that turned out to matter more than she realized, since the two drugs' tolerability profiles in that same head-to-head trial didn't track the assumption most patients bring into the room with them.
In clinic, correcting 'basically the same drug'
Tirzepatide, not semaglutide, and I'd say so directly rather than let her assume they're interchangeable. SURMOUNT-5 randomized 751 adults with obesity but no diabetes to head-to-head maximum-tolerated doses of each, and at 72 weeks tirzepatide produced a 20.2% mean weight reduction against semaglutide's 13.7% — 22.8kg versus 15.0kg, not a marginal difference dressed up as one.
I'd add the mechanistic reason that gap exists, since it changes how I'd counsel her: tirzepatide is a dual GIP and GLP-1 receptor agonist, while semaglutide acts on the GLP-1 receptor alone. The added GIP activity appears to act synergistically rather than just additively on appetite and energy balance, which is the leading explanation for why combining the two mechanisms outperforms either alone rather than simply summing two partial effects.
The GI tolerability data cut the other way, though, and deserve equal billing: gastrointestinal-adverse-event discontinuation was actually lower with tirzepatide in this trial, 2.7% versus 5.6% for semaglutide, so the usual assumption that a more potent GLP-1-pathway drug means a rougher ride isn't automatically true here.
Both real advantages noted, and I'd still flag one thing before we finalize this with her: semaglutide has a longer cardiovascular outcomes track record at this point, with SELECT's dedicated trial already read out, while tirzepatide's own cardiovascular outcomes data are still maturing. For her specifically — no established cardiovascular disease, no diabetes, obesity as the primary target — that gap doesn't change my recommendation, but it's the kind of asymmetry that could matter more in a different patient sitting in this same chair.
Agreed: start tirzepatide, titrated slowly, with the SURMOUNT-5 data and the mechanistic rationale explained to Renata directly so her expectations are grounded in trial evidence rather than an anecdotal comparison between a coworker and a cousin.
No real disagreement remained by the end of the visit; the endocrinologist's cardiovascular-evidence caveat was offered as context for future decisions, including a possible future switch, rather than a reason to reconsider today's choice.